Four months after its official establishment in February this year, the European Medicines Verification Organisation (EMVO) has appointed a new President. Designated to the post on June 19, Sonia Ruiz Moran replaced John Chave, former Secretary General of Pharmaceutical Group of the European Union (PGEU).
Sonia comes to the EMVO with a wealth of experience from the pharmaceutical sector, having led European Public Affairs at the General Pharmaceutical Council of Spain, since 2008. Heading up the Council’s Brussel’s office, she provided strategic advice in EU regulatory affairs, together with advocacy on initiatives with an impact on health issues. Sonia also liaised effectively with stakeholders and EU institutions.
Prior to joining the General Pharmaceutical Council of Spain, Sonia worked at Prisa, a leading media holding in Spanish-speaking countries, in the fields of Education and Entertainment, where she held managerial positions in the areas of product strategic development, market research and e-business intelligence.
Sonia holds an MBA from the University of Salamanca in addition to a degree in Law and a degree in Economics and Business Administration, both from the Pontificia de Comillas University (ICADE E-3).
Upon her designation, Sonia said: “The planning and design of a pan-European medicine verification system has been very complex. I believe that our mission now is about helping stakeholders in Member States to implement national verification systems that function at an equal level of efficacy, are interoperable and cost effective, in order to prevent falsified medicines from reaching patients, in accordance with EU legislation.”
Andreas M. WALTER
Director General a.i.
c/o EFPIA Communications
Phone: +32 2 626 25 55
The European Medicines Verification Organisation (EMVO) is a Luxembourgish non-profit organisation representing stakeholders united in securing the legal supply chain from falsified medicines. Its founding members are EFPIA, the European Federation of Pharmaceutical Industries and Associations, the EGA, the European Generic and Biosimilar medicines Association, PGEU, the Pharmaceutical Group of the European Union, GIRP, the European Association of Pharmaceutical Full-line Wholesalers and EAEPC, the European Association of Euro-Pharmaceutical Companies.